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Possible overlapping time frames of acquisition
and consolidation phases in object memory processes:
a pharmacological approach
Sven Akkerman,1 Arjan Blokland,2 and Jos Prickaerts1
1Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, European Graduate School
of Neuroscience; 2Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, European
Graduate School of Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands
In previous studies, we have shown that acetylcholinesterase inhibitors and phosphodiesterase inhibitors (PDE-Is) are able to
improve object memory by enhancing acquisition processes. On the other hand, only PDE-Is improve consolidation pro-
cesses. Here we show that the cholinesterase inhibitor donepezil also improves memory performance when administered
within 2 min after the acquisition trial. Likewise, both PDE5-I and PDE4-I reversed the scopolamine deficit model when ad-
ministered within 2 min after the learning trial. PDE5-I was effective up to 45 min after the acquisition trial and PDE4-I was
effective when administered between 3 and 5.5 h after the acquisition trial. Taken together, our study suggests that acetyl-
choline, cGMP, and cAMP are all involved in acquisition processes and that cGMP and cAMP are also involved in early and
late consolidation processes, respectively. Most important, these pharmacological studies suggest that acquisition processes
continue for some time after the learning trial where they share a short common time frame with early consolidation pro-
cesses. Additional brain concentration measurements of the drugs suggest that these acquisition processes can continue up
to 4–6 min after learning.
Memory is a highly complex cognitive function. The formation
of memories requires a sequence of complementary processes to
register, maintain, and retrieve events. Therefore, it is common
to segregatememory processes into an acquisition, consolidation,
and retrieval phase.When testing cognition enhancing properties
of drugs, it is particularly relevant to dissociate its effects on acqui-
sition, consolidation, and retrieval, particularly given the accu-
mulating evidence that these different memory processes rely
on distinct underlying neurobiological mechanisms (Izquierdo
et al. 2006;Winters et al. 2008). This would not only lead to a bet-
ter understanding of the properties of a drug, but also of neurobi-
ological mechanisms underlying memory processes.
Memory can be tested inwide array of behavioral animal par-
adigms. However, few of these models allow for an evaluation of
effects on the different memory subprocesses. One-trial learning
paradigms, such as the passive avoidance test, fear conditioning,
and the object recognition test (ORT) enable researchers to evalu-
ate memory-enhancing effects of drugs on individual memory
components. Typically, these tests consist of an acquisition trial
in which information is presented, and a test trial in which the in-
formation has to be retrieved. In these paradigms, the timing of
drug administration determines which memory process is affect-
ed (Abel and Lattal 2001; van Goethem et al. 2012). That is,
when a drug is administered before the acquisition trial, it is capa-
ble of influencing acquisition processes, whereas if the drug is
given after the acquisition trial it can be assumed to affect consol-
idation, because acquisition processes are already completed. On
the same rationale, drug administration shortly before the test tri-
al will only have an effect on retrieval.
In a previous study, using the object recognition task, we
showed that cholinesterase inhibitors (AChE-Is) metrifonate and
donepezil enhanced acquisition processes but not consolidation
processes, likely to be mediated via an increase in the neurotrans-
mitter acetylcholine (ACh) in the synaptic cleft (Prickaerts et al.
2005). On the other hand, phosphodiesterase type 5 inhibitors
(PDE5-Is) affect acquisition and early consolidation processes via
an increase in intracellular cyclic guanosine monophosphate
(cGMP)/protein kinase G (PKG) signaling, when administered
before or directly after learning, respectively (Devan et al. 2004,
2007; Prickaerts et al. 2005; Domek-Lopacinska and Strosznajder
2008; van Donkelaar et al. 2008; Bollen et al. 2014). Also, we
found that the phosphodiesterase type 4 inhibitor (PDE4-I) roli-
pram, which increases cyclic adenosine monophosphate
(cAMP)/protein kinase A (PKA) signaling, improves both acquisi-
tion and late consolidation processes when administered before
or at 3 h after learning (Rutten et al. 2006, 2007; Bollen et al.
2014). These findings provide further support for the notion
that acquisition and consolidation processes can be associated
with dissociable neurobiological processes.
To more accurately determine the exact time windows of
acquisition and consolidation processes occur, we administered
donepezil, vardenafil, or rolipram at several specific time points
after the acquisition trial. The capability of each drug to improve
acquisition and/or consolidation was tested by assessing its
potential to prevent natural forgetting in a 24-h intertrial inter-
val. Additionally, we tested the effects of the drugs using a 1-h
interval against the muscarinic receptor antagonist scopolamine,
which is commonly used as a memory deficit model and
specifically blocks acquisition processes (Rutten et al. 2006;
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Winters et al. 2006; Klinkenberg and Blokland 2010). Further-
more, plasma and brain concentrations of the cognition enhanc-
ing drugs were measured at several time points after injection, to
find out their relationship with the onset of their behavioral
effects.
Results
Effects of donepezil
The effects of donepezil treatment on the exploration measures
are shown in Table 1. In the 1-h delay interval combinedwith sco-
polamine, donepezil and/or scopolamine did not affect the object
exploration times (F(6,49) ¼ 1.84, n.s.) in T1 and T2 (F(6,49) ¼ 1.20,
n.s.). Similarly, after the 24-h retention delays, no effects of done-
pezil were found on the exploration levels in T1 (F(8,63) ¼ 1.27,
n.s.) and T2 (F(8,63) ¼ 1.11, n.s.).
Significant between-group differences on d2 were found in
the scopolamine deficit model (F(8,63) ¼ 7.67, P, 0.001) and nat-
ural forgetting paradigm (F(8,63) ¼ 3.49, P, 0.01), using one-way
ANOVAs. When injected after scopolamine treatment, donepezil
attenuated the scopolamine-induced deficit when injected
directly up to 2 min after T1, but not when injected after this
time point (see Fig. 1A). This shows that donepezil treatment im-
proved memory performance after a 24-h retention delay when
injected up to 2 min after T1, but not when injected at 4 min or
longer post-T1 intervals (Fig. 1B).
Effects of vardenafil
Table 1 shows the effects of vardenafil treatment on the explora-
tion measures. In the 24-h retention delays, vardenafil did not af-
fect object exploration in T1, (F(8,63) ¼ 1.83, n.s.), but exploration
differences were found in T2, (F(8,63) ¼ 2.13, P, 0.05). However,
Table 1. Treatment conditions, exploration levels (mean (+SEM)), and number (n) of rats in the object recognition task
ORT interval Model Treatment Timing n e1 e2
Donepezil conditions 1 h sal vehicle 0 min 8 18.0 (1.5) 24.3 (2.5)
scop vehicle 0 min 8 26.3 (3.3) 27.0 (2.4)
scop dpz 0 min 8 27.4 (3.8) 26.2 (3.7)
scop dpz 2 min 8 21.8 (2.3) 19.0 (2.0)
scop dpz 4 min 8 19.4 (1.1) 21.4 (2.9)
scop dpz 15 min 8 22.4 (1.6) 24.3 (2.3)
scop dpz 30 min 8 23.0 (2.6) 21.8 (2.0)
24 h - vehicle 0 min 8 19.8 (1.4) 18.2 (2.9)
- dpz 0 min 8 21.9 (2.0) 18.9 (2.1)
- dpz 2 min 8 17.9 (1.3) 24.4 (1.3)
- dpz 4 min 8 23.7 (3.3) 24.2 (1.9)
- dpz 15 min 8 19.2 (1.8) 19.0 (2.3)
- dpz 30 min 8 23.5 (1.5) 19.4 (1.9)
Vardenafil conditions 24 h - vehicle 0 min 8 19.8 (1.4) 18.2 (2.9)
- var 0 min 8 17.2 (1.3) 19.4 (1.6)
- var 2 min 8 15.4 (1.3) 14.3 (1.0)
- var 4 min 8 15.3 (1.6) 17.6 (2.0)
- var 15 min 8 19.6 (1.5) 21.4 (2.3)
- var 30 min 8 15.5 (1.3) 18.5 (2.1)
- var 45 min 8 20.0 (2.8) 24.1 (2.2)
- var 60 min 8 20.5 (2.0) 22.6 (1.3)
- var 75 min 8 20.6 (1.8) 23.6 (3.5)
Rolipram conditions consolidation 1 h sal vehicle 0 min 8 18.0 (1.5) 24.3 (2.5)
scop vehicle 0 min 8 26.3 (3.3) 27.0 (2.4)
scop roli 0 min 8 22.2 (2.9) 18.4 (1.7)
scop roli 2 min 8 23.4 (3.5) 17.1 (3.2)∗
scop roli 4 min 8 17.1 (1.3) 16.4 (2.4)∗
scop roli 15 min 8 20.7 (2.5) 20.2 (1.7)
scop roli 30 min 8 23.4 (2.6) 16.5 (2.4)∗
24 h early consolidation – vehicle 0 min 8 19.8 (1.4) 18.2 (2.9)
– roli 0 min 8 17.2 (1.7) 17.2 (1.2)
– roli 2 min 8 14.4 (0.8) 18.7 (1.1)
– roli 4 min 8 16.3 (0.9) 18.8 (2.2)
– roli 15 min 8 18.4 (1.2) 18.3 (1.6)
– roli 30 min 8 17.7 (1.6) 17.0 (1.5)
24 h late – vehicle 2.5 h 24 19.9 (1.5) 20.4 (1.4)
– roli 2.5 h 24 24.5 (1.5)∗ 27.3 (1.7)∗∗
– vehicle 3 h 23 21.8 (1.5) 24.0 (1.5)
– roli 3 h 24 24.1 (1.6) 28.7 (1.6)∗
– vehicle 4 h 22 19.9 (3.6) 22.0 (1.9)
– roli 4 h 22 23.1 (2.3) 25.0 (1.6)
– vehicle 5 h 20 18.4 (1.5) 22.9 (2.1)
– roli 5 h 24 24.5 (2.1)∗ 27.4 (2.0)
– vehicle 5.5 h 24 18.8 (1.4) 22.1 (1.5)
– roli 5.5 h 23 23.4 (1.9) 26.9 (1.7)∗
– Vehicle 6 h 21 19.7 (1.6) 22.1 (1.9)
– roli 6 h 24 24.1 (1.5) 30.8 (1.7)∗∗
Scopolamine (scop) or saline (sal) was always administered 30 min prior to T1. Vehicle, donepezil (dpz), vardenafil (var), and rolipram (roli) were always admin-
istered at specific time points after T1, indicated in the Timing column and e1 and e2 are the total amounts of exploration during T1 and T2, respectively.
Significant exploration differences from the vehicle condition are indicated with asterisks, one-sample t-test, (∗) P, 0.05; (∗∗) P, 0.01.
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post-hoc analysis (LSD) showedno significant differences in e2 be-
tween the vardenafil conditions and vehicle.
Vardenafil reversed the scopolamine-induced deficits only
when injected immediately or 2 min after T1 (see Fig. 2A).
Differences in d2 measures were found between groups in the
24-h delay interval, (F(8,63) ¼ 2.48, P, 0.05). Vardenafil treatment
improved memory performance in the 24-h delay interval, when
applied between 0 until 45 min after T1, but not when injected at
a later time point (Fig. 2B).
Effects of rolipram
The effects of rolipram treatment on the exploration indices are
shown in Table 1. In the 1-h retention sessions, there were no dif-
ferences in exploration during T1, (F(6,49) ¼ 1.51, n.s.); however,
exploration differences were present in T2, (F(6,49) ¼ 3.06, P,
0.05). Post-hoc analysis (LSD) revealed that all rolipram-treated
conditions had lower exploration levels in T2, compared to the ve-
hicle condition. In the 24-h retention intervals, rolipram did not
affect object exploration in T1 and T2, (F(5,42) ¼ 2.09, n.s.) and
(F(5,42) ¼ 0.16, n.s.), respectively.
Significant differences were found in discrimination perfor-
mance between the treatment conditions of the 1-h retention ex-
periment, (F(6,49) ¼ 4.06, P, 0.01). Post-hoc analysis (LSD)
revealed that only animals that received rolipram treatment at 2
min after T1 had significantly higher discrimination compared
to vehicle-treated animals (Fig. 3A). No significant differences
were found (F(5,42) ¼ 1.18, n.s.) between treatment conditions in
the 24-h retention experiment (Fig. 3B).
In the rolipram late consolidation experiment, independent
samples t-testswere performed between the vehicle- and rolipram-
treated animals at each separate injection time point, which
showed that animals had object discrimination when treated
with rolipram between 3 and 5.5 h after T1 (see Fig. 4).
Drug exposure–time relationships in rats following
administration of vardenafil, rolipram, and donepezil
The results of the pharmacokinetic measurements are shown in
Tables 2 and 3. Donepezil levels more than lower limit of quanti-
fication (LLOQ) in the brain at 4 min after p.o. injection. The un-
bound brain/plasma ratio varied between 16.66 (10 min) to 6.40
Figure 1. Effects of donepezil treatment on discrimination performance in an object recognition task using a 1-h interval in combination with scopol-
amine (A) or a 24-h retention interval (B). Asterisks indicate a difference from scopolamine/vehicle-treated (A) or vehicle-treated (B) animals, least signifi-
cant difference (LSD): (∗∗) P, 0.01; (∗∗∗) P, 0.001, plus signs indicate a difference from the saline/vehicle-treated animals, +++P, 0.001 and
differences from zero are indicated with hashes, one-sample t-test, #P, 0.05; ##P, 0.01; ###P, 0.001.
Figure 2. Effects of vardenafil treatment on discrimination performance in an object recognition task using a 1 h interval in combination with
scopolamine (A): adapted from a previous study (Akkerman et al. 2015) or a 24-h retention interval (B). Asterisks indicate a difference from scopol-
amine/vehicle-treated (A) or vehicle-treated (B) animals, LSD, (∗) P, 0.05; (∗∗) P, 0.01; (∗∗∗) P, 0.001, plus signs indicate a difference from the
saline/vehicle-treated animals (A), LSD, ++ P, 0.01; +++ P, 0.001 and differences from zero are indicated with hashes, one-sample t-test, # P,
0.05; ## P, 0.01; ### P, 0.001.
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(60 min) and unbound brain donepezil levels .IC50 were detect-
ed 10–60 min after oral administration (see Table 2).
In a previous study we showed that vardenafil levels reached
values .LLOQ in both plasma and brain, 4 min after p.o. injec-
tion (Akkerman et al. 2015). The reported unbound brain/plasma
ratio varied between 1.61 (4 min) to 0.45 (20 min) and unbound
brain and plasma levels of vardenafil reached IC50 values around
10min after administration and remained .IC50 until 60min af-
ter administration.
Rolipram was given i.p. and reached .LLOQ levels in the
brain at 2 min after injection. The unbound brain/plasma ratio
varied between 2.50 (4 min) to 6.40 (30 min) and unbound brain
and levels of rolipram reached values.IC50 at 4min after admin-
istration where they remained until 60 min after administration
(see Table 3).
Discussion
In this study we examined the effects of different drugs that previ-
ously have been characterized as having an effect on acquisition,
early consolidation, or late consolidation, i.e., donepezil, varde-
nafil, and rolipram, respectively. Here we examined the effects
of these drugs in a model of scopolamine-induced acquisition im-
pairment and amodel of natural forgetting using a 24-h retention
interval. All drugswere already detectable in the brain 2–4min af-
ter injection. Both donepezil and vardenafil reached central levels
above IC50 between 10 and 60min after injection, while rolipram
already reached IC50 within 4min. In accordancewith one of our
previous studies (Akkerman et al. 2015), we found that all drugs
were able to reverse a scopolamine-induced short-term memory
deficit when injected within a window of 2 min post-T1. These
current findings together with a previous study (Akkerman et al.
2015) then indicate that donepezil, vardenafil, and rolipram re-
verse the scopolamine-induced short-term memory deficit.
These effects are assumed to be related to acquisition processes,
which appear to linger on for severalminutes after the acquisition
trial. Donepezil and rolipram also prevented normal forgetting
when injected within 2 min after the acquisition trial. These
data further suggest an effect on acquisition processes. In the
24-h delay condition, the treatment window of vardenafil lasted
up to 45 min, indicating that this represents the window for
cGMP-mediated early consolidation processes. Finally, the data
of rolipram in the 24-h delay interval indicate that cAMP-mediat-
ed late consolidation processes take place between 3 and 5.5 h
after acquisition. Taken together, our study suggests that ACh,
cGMP, and cAMP are all involved in acquisition processes and
that cGMPand cAMPare also involved in early and late consolida-
tion processes, respectively.
ACh is considered to be an important neurotransmitter for
memory function. However, the specific role of ACh in memory
formation is still poorly understood, possibly because different
stages of memory are differentially affected by it (Micheau and
Marighetto 2011). The biphasic hypothesis of cholinergic modu-
lation of memory processes states that ACh enhances the level of
afferent input of new information to the cortex via its nicotinic re-
ceptors (Hasselmo 2006). This way, high levels of ACh would lead
to efficient acquisition and encoding of new information (Rasch
et al. 2006).
It has been shown that post-learning blockage of muscarinic
or nicotinic receptors alone does not impair consolidation pro-
cesses (Rush 1988; Spangler et al. 1988; Anagnostaras et al.
1999; Miranda et al. 2003; Rasch et al. 2006;). In addition, the
Figure 3. Effects of rolipram treatment on discrimination performance in an object recognition task using a 1-h interval in combination with
scopolamine (A) or a 24-h retention interval (B). Asterisks indicate a difference from scopolamine/vehicle-treated (A) or vehicle-treated (B) animals,
LSD, (∗) P ¼ 0.062; (∗) P, 0.05; (∗∗∗) P, 0.001, plus signs indicate a difference from the saline/vehicle-treated animals (A), LSD, ++ P, 0.01 and dif-
ferences from zero are indicated with hashes, one-sample t-test, # P, 0.05; ## P, 0.01; ### P, 0.001.
Figure 4. Effects of rolipram treatment on discrimination performance
in an object recognition task using a 24-h retention interval. Asterisks in-
dicate a difference from vehicle-treated animals, independent samples
t-tests; (∗) P, 0.05; (∗∗) P, 0.01 and differences from zero are indicated
with hashes, one-sample t-test, # P, 0.05; ## P, 0.01.
Acquisition and consolidation processes overlap
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retention interval we used was 1 h, which is too short to implicate
long-termmemory consolidation processes. Therefore, we assume
that, in our study, the muscarinic antagonist scopolamine-in-
duced memory impairment was acquisition related and not due
to deficient consolidation.
Surprisingly, the results of the present study showed that, in a
24-h retention interval, donepezil prevented natural forgetting of
object information in rats when administered within 2 min after
the T1. However, when injected after 4, 15, or 30 min after T1,
donepezil was no longer effective. Donepezil showed an exactly
identical effective window in the scopolaminemodel. These find-
ings are in accordance with findings from other one-trial recogni-
tion studies testing acetylcholinesterase inhibitors (AChE-Is)
using 24-h delay intervals. Lamirault et al. (2003) found that
AChE-I (-)-9-dehydrogalanthaminium bromide successfully im-
proved object and place memory, when injected 20 min before
or directly after the acquisition phase. Also another AChE-I, tac-
rine, was shown to be effective, when administered directly after
learning, in a social recognition task (Gheusi et al. 1994). These
memory-enhancing effects of donepezil on long-term memory
are unlikely to be consolidation related. On the contrary, accord-
ing to the biphasic hypothesis, the increase in cholinergic activity
would lead to a reduction in consolidation efficiency (Hasselmo
et al. 2004; Hasselmo and Giocomo 2006; Rasch et al. 2006).
Our behavioral findings show that the window during which
cholinergic intervention is able to still influence what is probably
acquisition lasts for at least 12 min (taking into account the injec-
tion interval and brain penetration) after a learning trial.
In the 24-h retention sessions, vardenafil improved object
memory when injected up to 45 min after the learning trial.
This finding is in linewith our previous studies inwhichwe found
an effect when vardenafil was administered immediately after the
acquisition trial but notwhen injected 1 h after the acquisition tri-
al (Prickaerts et al. 2002; Rutten et al. 2007). The present data pro-
vide further support that enhancing effects of vardenafil on
memory consolidation processes can be found up to 50 min after
T1 (taking into account the injection interval and brain penetra-
tion). The effect of vardenafil on consolidation processes is likely
to be mediated via glutamatergic stimulation of post-synaptic
GMP/PKG signaling (Lu et al. 1999; Bollen et al. 2014).
In contrast to the current 24-h retention experiment, varde-
nafil could only reverse a scopolamine-induced acquisition deficit
when injected within 2 min after the learning trial (see also
Akkerman et al. 2015). This effective window shows surprising
similarities to our current findings with donepezil and may sug-
gest that the effect of vardenafil on long-term memory is partly
mediated through acquisition processes when treatment is
performed shortly after the acquisition trial. Such an effect on ac-
quisition might be explained by an increased release of neuro-
transmitters, including ACh and glutamate, as a results of
presynaptic stimulation of cGMP/PKG signaling by vardenafil
(Arancio et al. 1995).
Table 2. Pharmacokinetic measurements of donepezil in the rat after oral administration
Parameter
Time (min)
2 4 6 10 20 30 60
Cb (ng/g) 0.00 (0.00) 1.70 (1.70) 7.29 (2.57) 39.73 (9.60) 111.65 (65.35) 91.80 (10.22) 83.97 (5.95)
Cb,u (nM) 0.00 (0.00) 0.79 (0.79) 3.36 (1.18) 18.32 (4.43) 51.49 (30.14) 42.33 (4.71) 38.72 (2.74)
Cb,u:IC50 0.00 (0.00) 0.14 (0.14) 0.59 (0.21) 3.21 (0.78) 9.03 (5.29) 7.43 (0.83) 6.79 (0.48)
Cp (ng/mL) ,LLOQ (NA) ,LLOQ (NA) ND 1.73 (1.39) ND 4.03 (0.89) 5.15 (0.34)
Cp,u (nM) ND (NA) ND (NA) ND 2.05 (1.64) ND 4.76 (1.05) 6.09 (0.40)
Cp,u:IC50 ND (NA) ND (NA) ND 0.36 (0.29) ND 0.84 (0.18) 1.07 (0.07)
Cb:Cp ND (NA) ND (NA) ND 42.75 (37.30) ND 24.28 (3.37) 16.41 (1.40)
Cb,u:Cp,u ND (NA) ND (NA) ND 16.66 (14.54) ND 9.46 (1.31) 6.40 (0.55)
Mean (+SEM) values of pharmacokinetic parameters (n ¼ 3/time point) of donepezil at different time points after T1, 1 mg/kg, p.o. Total plasma (Cp) or total
brain (Cb) vardenafil concentration is reported as ng/mL or ng/g, respectively. The unbound fractions (Fu) of plasma (0.449) and brain (0.175) homogenate
were obtained from Shen et al. (2011). Unbound plasma (Cp,u) and unbound brain (Cb,u) concentrations of donepezil are reported in nM and were calculated
as follows; Cu ¼ (Ctotal/MW) × 1000 × Fu, with the MW of donepezil being 379.49 g/mol. Both Cb,u and Cp,u were compared to the IC50 of donepezil, 5.7 nM
(5.7 nM, Kosasa et al. 2000). ND ¼ not determined, NA ¼ not applicable.
Table 3. Pharmacokinetic measurements of rolipram in the rat after intraperitoneal administration
Parameter
Time (min)
2 4 6 10 20 30 60
Cb (ng/g) 3.33 (1.77) 16.10 (6.44) 29.07 (1.99) 23.33 (5.95) 14.69 (2.42) 8.10 (0.69) 4.81 (1.20)
Cb,u (nM) 2.32 (1.23) 11.22 (4.49) 20.27 (1.39) 16.27 (4.15) 10.24 (1.68) 5.65 (0.48) 3.36 (0.83)
Cb,u:IC50 0.77 (0.41) 3.74 (1.50) 6.76 (0.46) 5.42 (1.38) 3.41 (0.56) 1.88 (0.16) 1.12 (0.28)
Cp (ng/mL) ND 8.31 (5.11) ND ND ND 0.98 (0.10) ,LLOQ (NA)
Cp,u (nM) ND 7.79 (4.79) ND ND ND 0.92 (0.10) ND (NA)
Cp,u:IC50 ND 2.60 (1.60) ND ND ND 0.31 (0.03) ND (NA)
Cb:Cp ND 3.36 (1.88) ND ND ND 8.61 (1.70) ND (NA)
Cb,u:Cp,u ND 2.50 (1.40) ND ND ND 6.40 (1.26) ND (NA)
Mean (+SEM) values of pharmacokinetic parameters (n ¼ 3/time point) of rolipram at different time points after T1, 0.03 mg/kg, i.p. Total plasma (Cp) or total
brain (Cb) rolipram concentration is reported as ng/mL or ng/g, respectively. The unbound fractions (Fu) of plasma (0.258) and brain (0.192) homogenate were
obtained from Guo et al. (2009). Unbound plasma (Cp,u) and unbound brain (Cb,u) concentrations of rolipram are reported as nM and were calculated as
follows: Cu ¼ (Ctotal/MW) × 1000 × Fu, the MW of rolipram being 275.34 g/mol. Both Cb,u and Cp,u were compared to the IC50 for the rolipram
high-affinity-binding site (3 nM) (Barnette et al. 1995; MacKenzie and Houslay 2000). ND ¼ not determined, NA ¼ not applicable.
Acquisition and consolidation processes overlap
www.learnmem.org 33 Learning & Memory
 Cold Spring Harbor Laboratory Press on March 3, 2017 - Published by learnmem.cshlp.orgDownloaded from 
Surprisingly, the results obtained with rolipram treatment
within the first hour after T1 were very similar to those found
with donepezil; however, the effects were a bit less pronounced.
Rolipram only fully reversed the scopolamine-induced deficit
when injected at 2 min after T1, but an intermediate effect was
found when rolipram was injected immediately after T1, that is,
the d2 index of rats injected at 0min after T1washigher compared
to zero but not compared to vehicle-treated animals after
24 h. Also in the 24-h retention interval, an intermediate effect
of rolipram treatment was found within the first 2 min after T1.
In previous studies we never found that rolipram was effective
when injected directly after T1 using a 24-h delay interval
(Rutten et al. 2006, 2007, 2009; Bollen et al. 2014). However, in
those studies our injection times were on average about 4–10
min after the acquisition trial due to the injection procedures in-
cluding taking the rat from the apparatus and taking the injection
needle(s) (see Bollen et al. 2014).
Importantly, in the present study, we took great effort and
care to inject exactly at the intended time point after T1. This
might explain the lack of previous findings, as the current effects
of rolipram were very subtle. Rolipram increases the levels of
cAMP (Barad et al. 1998; Rutten et al. 2006), and presynaptical el-
evation of cAMP might induce the release of neurotransmitters,
including ACh (Schoffelmeer et al. 1986). Along similar lines, it
has been shown that acute administration of a cAMP analog,
directly after learning can improve long-termhabituation in crabs
(Romano et al. 1996). This effect might be related a short initial
spike in cAMP levels, immediately after learning (Izquierdo et al.
2006). In our study, a reinforcement of this initial spike, by roli-
pram treatment, may just have been sufficient to enhance the
memory trace via acquisition processes.
In agreement with our previous studies (Rutten et al. 2007;
Akkerman et al. 2014) we observed that rolipram improves late
consolidation processes when injected at 3 h after the acquisition
trial. We now demonstrated that rolipram is exactly effective
when given between 3 and 5.5 h after the acquisition trial.
This late consolidation window is likely to be dependent on post-
synaptic cAMP/PKA signaling (Barad et al. 1998; Rutten et al.
2006; Bollen et al. 2014) and therefore indicates that cAMP-medi-
ated late consolidation processes take place at this time.
Remarkably, in the scopolamine deficit model all drugs were
effective when injected within 2 min after T1. However, to deter-
mine the exact duration of the target processes, one has to know
the pharmacokinetics of each drug, because the drugs needs
some time to reach the brain instantly after peripheral administra-
tion. From the literature it is known that donepezil reaches max-
imumplasma levels 13min after i.p. injection at a dose of 1mg/kg
(Nakashima et al. 2006). Maximum plasma and brain concentra-
tions are reached simultaneously at 30 min after p.o. donepezil
administration (1mg/kg)with a half-life of about 1 h (Matsui et al.
1999). Thus, it seems that drug absorption following i.p. adminis-
tration is about twice as rapid as p.o. administration, although the
observed difference in the onset of behavioral effects is smaller
(Snape et al. 1999).
Our PK measurements appear to corroborate with these re-
ports. Although we already observed maximum concentrations
in brain andplasma at 20minpost-administration, the concentra-
tions at 30 min were almost identical to those observed byMatsui
et al. (1999). It is unknown what donepezil concentration is re-
quired in the brain for memory enhancement, though it is gener-
ally accepted that an IC50 is required for a biological effect. Here
we show that donepezil’sCb,u reached its IC50within 10min after
p.o. administration and remained at or above it for up to 1 h post-
dosing (Table 2). The latter is an important observation since it
explains that the effect of donepezil given at 0 and 2 min after
the acquisition trial cannot be explained via an effect on retrieval,
as one would expect that the administration at 4, 15, or 30min af-
ter T1 in the 1-h interval should also be effective if retrieval was
involved, i.e. all these administrations would result in brain con-
centrations well above IC50 at the time of retrieval (T2). Also,
based on the available PK, one can assume that donepezil brain
concentrations after the 24-h delay interval were too low for an ef-
fect on retrieval. Additionally, the 1-h interval is too short to im-
plicate late consolidation processes which are linked to long-term
memory. Taken together these findings indicate acquisition pro-
cesses as the most likely mechanism for the observed discrimina-
tion improvement.
Donepezil always improved memory when injected within
2 min after learning. Together with the IC50 this also suggests
that donepezil, i.e., ACh, is active within the first 12 min after
T1. Yet it cannot be ruled out that donepezil already affects acqui-
sition at unbound concentrations below its IC50, i.e., directly af-
ter the drug becomes centrally available. As we first detected
donepezil in the brain 4 min after p.o. administration, the win-
dow might actually persist for only 6 min after T1.
Vardenafil was detectable in the brain within 2 min and
reaches IC50 values at 10 min after p.o. injection (see Table 3).
Also based on PKmeasurements and behavioral data in our previ-
ous study (Akkerman et al. 2015), we argue that vardenafil is likely
to be involved in acquisition processes and that these processes
could extend at least 4–6 min after T1. This acquisition window
matches closely with the 6 min window found for donepezil. In
the current study, we further show that, when memory is not
impaired by scopolamine, vardenafil prevented natural forget-
ting when injected up to 45 min after T1, implying that the
cGMP/PKG pathway is involved in both acquisition and early
consolidation processes.
Rolipramhas been reported to reachmaximumplasma levels
15 min after oral administration (Krause and Kuhne 1988). In our
study rolipram was administered i.p., and is therefore likely to be
more rapidly absorbed into the bloodstream. Our PK measure-
ments showed that rolipram is present in the brain at 2 min after
injection and unbound rolipram reached the IC50 concentration
in the brain within 4 min after injection. The maximum concen-
tration was reached at 6 min and returned to IC50 at 1 h after in-
jection. Combined with the behavioral data, it can be argued that
rolipram may be actually active up to 4–6 min after learning.
Considering our finding in the scopolamine model, it is unlikely
that retrieval processes were affected by rolipram because, like
with donepezil, every administration time point resulted in a
brain concentration above IC50 at the time of retrieval (T2).
Furthermore, the half-life of rolipram is too short for any effective
concentrations at the time of retrieval after the 24-h retetention
interval. As the 1-h interval is too short to accommodate con-
solidation processes, these findings implicate that PDE4 is in-
volved in acquisition processes and again, these seem to extend
for 4–6 min after T1.
Our findings on the windows of effect of donepezil, vardena-
fil and rolipram suggest a temporal overlap, of at least 4–6 min,
between the acquisition and early consolidation phases of memo-
ry. This windowmight represent a transition between acquisition
processes and the consolidation stage of memory. The animals
were unable to acquire object information after T1, since they
have no access to the objects anymore. Also, as described above,
it is unlikely that donepezil enhances consolidation. Therefore,
it is possible that there are encoding processes that continue for
some time after stimulus exposure. Encoding refers to the forma-
tion of relations between events in episodic memory, based on
many kinds of information, such as temporal and categorical
(Lepage et al. 2000). It also entails novelty/familiarity evaluation
(Habib et al. 2003), and involves transperceptual processes operate
beyond perceptual processes (Lepage et al. 2001).
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In our experiment all drugs had a remarkably similar effective
window of 2 min post-T1, during which they were capable of re-
storing the scopolamine memory deficit. Combined with our PK
measurements, these data suggest that acquisition processes con-
tinue for 4–6 min after T1. Vardenafil prevented natural forget-
ting via cGMP/PKG early consolidation processes when injected
within 0–45min after T1. This shows that there is a 4–6min win-
dow of overlap between acquisition and consolidation processes,
duringwhich the transition fromacquisition into early consolida-
tion processes might take place. Furthermore, our data indicate
that cAMP/PKA signaling is crucially involved in late consolida-
tion processes between 3 and 5.5 h after T1. It would be interesting
to identify pathways that are active in-between 45min and 3 h af-
ter T1, which might link these cGMP and cAMP signaling path-
ways and investigate these in a similar fashion. Knowing the
complete cascades underlying long-term memory formation
may give us new insight and strategies to effectively treat cogni-
tive decline.
Materials and Methods
Animals
All experimental procedures were approved by the local ethical
committee of the Maastricht University for animal experiments
according to governmental guidelines. Forty-eight 5-mo-old
male Wistar rats (Charles River, The Netherlands) were used for
the behavioral studies and 42 of these rats were used for the phar-
macokinetics study (6 animals were not used). The animals were
housed individually in standard Makrolon Type III cages on saw-
dust bedding in an air-conditioned room (about 20˚C). They were
kept under a reversed 12/12-h light–dark cycle (lights on from
6 p.m. to 6 a.m.). Food and water were provided at libitum: water
was acidified (pH3) to prevent bacterial infections and refreshed
every week. Testing was done in the same room as where the ani-
mals were housed. A radio played softly, providing background
noise 24 h a day, also during testing.
Treatment
Each compound was freshly dissolved on every experimental day.
Donepezil (1mg/kg; generously given by Solvay Pharmaceuticals,
Weesp, TheNetherlands)was dissolved in saline and administered
p.o., the injection volume was 1 mL/kg. Vardenafil (1 mg/kg;
kindly donated by BAYER AG, Wuppertal, Germany) was dis-
solved in a vehicle containing 98% tylose (methyl-cellulose) solu-
tion (1%) and 2% tween 80, and was given orally (p.o.) at an
injection volume of 1 mL/kg. The same vehicle was used for
dissolving rolipram, which was given i.p. (1 mL/kg). For rolipram
(Sigma-Aldrich, Zwijndrecht, theNetherlands), a dose of 0.03mg/
kg was used in the 24-h retention interval sessions and 0.1 mg/kg
in the 1-h retention sessions in combination with scopolamine. A
fixed dose of 0.1 mg/kg scopolamine Hbr (Sigma-Aldrich) was
used as an acquisition-deficit model, and was also dissolved in sa-
line. Scopolamine was administered intraperitoneally (i.p.) at a
volume of 1 mL/kg. Doses, vehicles, and administration routes
were determined based on earlier studies using these drugs
(Prickaerts et al. 2005; Rutten et al. 2006, 2007).
Object recognition task
We used the ORT as described in previous studies (Prickaerts et al.
2002). Briefly, the apparatus consisted of a circular arena, 83 cm in
diameter. Half of the 40 cm high wall was made of gray polyvinyl
chloride (RAL 7035), and the other half of transparent polyvinyl
chloride. Two objects were placed at symmetrical positions about
10 cm away from the gray wall. Four different sets of objects were
used, and the objects could not be displaced by the animals.
A test session comprised two trials. During the first trial (T1),
the apparatus contained two identical objects (samples). After the
first 3 min exploration period, the rat was put back in its home
cage. Subsequently, after a delay interval of 1 or 24 h, the rat
was put back in the apparatus for the second trial (T2) that also
lasted 3min. In T2, two dissimilar objects, a familiar one (the sam-
ple) and a new one, were used. The times spent exploring each ob-
ject during T1 and T2 were recorded manually with specially
developed software and stored on a personal computer. The exper-
imenter who scored (live scoring) the behavior was blind toward
the treatment conditions of the rats.
Explorationwas defined as follows: directing the nose toward
the object at a distance of nomore than 2 cm and/or touching the
object with the nose. Leaning or climbing on objects was not con-
sidered to be exploration. Each object was available in triplicate,
so none of the two objects from the first trial had to be used as
the familiar object in the second trial. In addition, all combina-
tions and locations of objects were used in a balanced manner
to reduce potential biases due to preferences for particular loca-
tions or objects.
Experimental procedure and treatment conditions
First, the animals were adapted to the testing procedure and drug
administration procedures. During this training phase, the rats
were submitted to one 3 min habituation trial in the empty arena
on 2 consecutive days. One day later, a 1-h interval training ses-
sion (comprising two 3-min trials, i.e., T1 and T2) was performed
in which the animals are not subjected to any injections. During
this and following sessions, two different objects were present.
This was followed by a second training session in which a 24-h in-
terval test was applied, also without injecting the animals. On a
subsequent day, animals were familiarized to the administration
procedure via saline injections. Animals received two saline injec-
tions, one i.p. injection and one p.o. (gavage) injection, both
1mL/kg. Trainingwas completedwith a 1-h interval test, together
with an i.p. injection, 30 min before T1 and a p.o. injection,
directly after T1. On both occasions saline was administered
(1 mL/kg). After this, drug testing started.
To specifically investigate the effects of donepezil, vardenafil,
and rolipram on acquisition processes, a 1-h delay interval was
used in combination with a scopolamine-induced memory defi-
cit. One hour intervals were tested three times a week, on
Monday, Wednesday, and Friday, and Tuesday and Thursday
were used as washout days.
Since we expected the drug treatments to improve memory
consolidation performance, we also tested each drug in a 24-h de-
lay interval. Normally, rats show nomore discrimination between
the objects after such a delay (Akkerman et al. 2012). Each week
two test sessions were performed, one session on Monday (T1)
and Tuesday (T2) and the other one comprised Thursday (T1)
and Friday (T2).
Testing conditions
We used 24 rats to examine drug effects in a narrow time window.
Donepezil, vardenafil, and rolipram were injected at several spe-
cific time points, starting directly after T1. At 1-h delay intervals,
these drugs were injected at 0, 2, 4, 15, or 30 min after T1, com-
bined with scopolamine treatment at 30 min before T1. In the
control conditions, animals received either scopolamine, or just
saline (1 mL/kg, i.p.) 30 min before T1 in combination with the
vehicle of vardenafil and rolipram (1 mL/kg, p.o.) immediately
(0 min) after T1.
At 24-h delay intervals, donepezil or vardenafil was injected
0, 2, 4, 15, 30, 45, 60, or 75 min after T1. Rolipramwas injected at
0, 2, 4, 15, or 30 min after T1 when tested in the 24-h delay inter-
vals. As a control condition, the vehicle of vardenafil and rolipram
was injected (1 mL/kg, p.o.) immediately (0 min) after T1. The
same rats were used for each drug and interval condition (31 ses-
sions in total). Another batch of 24 rats was used for an additional
experiment to determine the effective treatment window for roli-
pram on late consolidation. In the late consolidation experiment,
rolipram was tested when injected at 2.5, 3, 4, 5, 5.5, and 6 h after
T1; each time point had its own vehicle condition.
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Pharmacokinetics
Forty-two rats of the group that were used for behavioral test were
used for the determination of plasma and brain concentrations
over the first hour following its oral administration. Animals
were sacrificed for blood and brain sampling at 2, 4, 6, 10, 20,
30, and 60 min after dosing. Twenty-one animals were used for
donepezil measurements and 21 animals for rolipram (n ¼ 3 per
time point). The pharmacokinetics of vardenafil, using similar
Materials andMethods, have been reported elsewhere (Akkerman
et al. 2015). Blood was drawn from the saphenus vein using
heparin-coated tubes, which were temporarily stored on wet ice,
and immediately after blood collection the animal was decapitat-
ed. The complete brain was collected, rinsed with ice-cold saline,
placed in a cup, weighed, and immediately frozen on dry ice.
Plasma was isolated using centrifugation (1500g for 10 min
at 4˚C) and pipetted into Eppendorf vials. Plasma and brain
samples were stored at 280˚C until bioanalytical processing.
Vardenafil quantification was performed at BioDuro (Pharmaceu-
tical Product Development, Inc., Shanghai, PRC), rolipram and
donepezil were quantified by Agilux Laboratories (Worcester,
MA). For bioanalytical sample preparation, plasma was used as
is, whereas brain samples were first homogenized in a fourfold
volume (w/v) of water (vardenafil) or 80:20 water:acetonitrile
(rolipram, donepezil). Both matrices were processed for drug
quantification using the liquid–liquid extraction methodology
followed by a characterized liquid chromatography-tandem
mass spectrometry (LC-MS/MS) assay. Standard curves were pre-
pared in control matrices, an appropriate dynamic range was
achieved, and instrument settings and potentials were adjusted
to optimize theMS signal for vardenafil. Vardenafil data were pro-
cessed using the Analyst Software, version 1.4.2 (AB Sciex Inc.,
Ontario, Canada), while for rolipramand donepezil datawere pro-
cessed using the Masslynx software with the Quanlynx applica-
tion manager (Waters Ltd.). The LLOQ of vardenafil was
0.05 ng/mL for plasma and 0.02 ng/mL for brain. For rolipram
and donepezil, the LLOQ was 0.5 ng/mL for plasma and 0.25
ng/mL for brain. The unbound fractions (Fu) of plasma and brain
were obtained from the literature and unbound plasma (Cp,u) and
unbound brain (Cb,u) concentrations were calculated as follows:
Cu ¼ (Ctotal/MW) × 1000 × Fu, and reported in nM. Additionally,
plasma and brain concentrations were compared to IC50 values
and the ratio between brain (Cb) and plasma (Cp) concentrations
was calculated by dividing Cb by Cp.
Statistical analysis
The basic output measures in the ORT are the times spent by rats
in exploring each object during T1 and T2. The time spent in ex-
ploring the two identical sample objects in T1 will be represented
by “a1” and “a2”. The time spent in T2 in exploring the sample
and the novel object will be represented by “a3” and “b,” respec-
tively. The following variables were calculated: e1 ¼ a1 + a2,
e2 ¼ a3 + b, and d2 ¼ (b – a3)/e2. e1 and e2 aremeasures of the to-
tal time spent investigating both objects during T1 and T2, respec-
tively. The d2 index is a relative measure of discrimination
corrected for the level of exploration in the test trial (e2).
One-sample t-statistics were performed to assess whether d2
was different from zero, since random exploration in T2 would re-
sult in equal exploration of both objects. Between-group effects
on e1, e2, and d2 measures were also assessed using one-way
ANOVA. In case of significant differences, post-hoc comparisons
with the control conditions were performed using Fisher LSD
tests.
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